Ces radiol. 2013, 67(1):19-24

Pre-bioptical imaging of gliomas using PET/CT with application of 18F-fluorothymidineOriginal article

Jiří Ferda1, Eva Ferdova1, Karel Mařík2, Jan Mraček1, Ondřej Hes2
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Oddělení neurochirurgie FN, Plzeň
3 Šiklův ústav patologické anatomie LF UK a FN, Plzeň

Aim: To evaluate a value of the proliferation activity assessment in gliomas using PET/CT with the application of 18F-fluorothymidine.

Method: The sample of 21 tumors was analyzed (in patients with mean age 50.3, range 26-72 years), 18F-FLT-PET/CT was performed before confirmation of the histological diagnosis, and the level of 18F-FLT accumulation was compared with the assessment of proliferation activity using immunohistochemistry evaluation of Ki-67.

Results: Following results were reached accuracy 90.4% (19/21), sensitivity 90% (9/10), specificity 90.9 (10/11), positive predictive value 90% (9/10) and negative predictive value 90.9% (10/11).

Conclusion: 18F-FLT-PET/CT is the valuable test to estimate the proliferation activity of gliom before biopsy, could leads to better targeting biopsy and early detection of malignant turnover of glioma.

Keywords: 18F-FLT, PET/CT, proliferation activity, glioma
Grants and funding:

Podpořeno projektem Ministerstva zdravotnictví ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň.

Accepted: March 15, 2012; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Ferdova E, Mařík K, Mraček J, Hes O. Pre-bioptical imaging of gliomas using PET/CT with application of 18F-fluorothymidine. Ces radiol. 2013;67(1):19-24.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Langen P, Etzold G, Hintsche R, Kowollik G. 3'-Deoxy-3'-fluorothymidine, a new selective inhibitor of DNA-synthesis. Acta Biol Med Ger 1969; 23(6): 759-766.
    2. Meisel H, Reimer K, von Janta-Lipinski M, Bärwolff D, Matthes E. Inhibition of hepatitis B virus DNA polymerase by 3'-fluorothymidine triphosphate and other modified nucleoside triphosphate analogs. J Med Virol 1990; 30(2): 137-141. Go to original source... Go to PubMed...
    3. Choi SJ, Kim JS, Kim JH, et al. [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005; 32(6): 653-659. Go to original source... Go to PubMed...
    4. Jeong SY, Lim SM. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol 2012; 39(7): 977-981. Go to original source... Go to PubMed...
    5. Idema AJ, Hoffmann AL, Boogaarts HD, et al. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med 2012; 53(12): 1904-1910. Go to original source... Go to PubMed...
    6. Shinomiya A, Miyake K, Okada M, et al. 3'-Deoxy-3'-[(18)F]-fluorothymidine ([(18)F]-FLT) transport in newly diagnosed glioma: correlation with nucleoside transporter expression, vascularization, and blood-brain barrier permeability. Brain Tumor Pathol 2013 [Epub ahead of print] PubMed PMID: 23423309. Go to original source... Go to PubMed...
    7. Willaime JM, Turkheimer FE, Kenny LM, Aboagye EO. Quantification of intra-tumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography. Phys Med Biol 2013; 58(2): 187-203. Go to original source... Go to PubMed...
    8. Axente M, He J, Bass CP, et al. Tumour microenvironment heterogeneity affects the perceived spatial concordance between the intratumoural patterns of cell proliferation and 18F-fluorothymidine uptake. Radiother Oncol 2012; 105(1): 49-56. Go to original source... Go to PubMed...
    9. Schiepers C, Dahlbom M, Chen W, et al. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med 2010; 51(5): 720-727. Go to original source... Go to PubMed...
    10. Hong IK, Kim JH, Ra YS, Kwon do H, Oh SJ, Kim JS. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor. J Comput Assist Tomogr 2011; 35(6): 679-684. Go to original source... Go to PubMed...
    11. Enslow MS, Zollinger LV, Morton KA, et al. Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med 2012; 37(9): 854-861. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content